Department of Orthopedic Surgery, Rush University Medical Center, Chicago, Illinois, USA.
Department of Orthopedics, Tianjin Medical University General Hospital, Tianjin, China.
Ann Rheum Dis. 2020 May;79(5):635-645. doi: 10.1136/annrheumdis-2019-216713. Epub 2020 Mar 10.
In this study, we aim to determine the effect of metformin on osteoarthritis (OA) development and progression.
Destabilisation of the medial meniscus (DMM) surgery was performed in 10-week-old wild type and AMP-activated protein kinase (AMPK)α1 knockout (KO) mice. Metformin (4 mg/day in drinking water) was given, commencing either 2 weeks before or 2 weeks after DMM surgery. Mice were sacrificed 6 and 12 weeks after DMM surgery. OA phenotype was analysed by micro-computerised tomography (μCT), histology and pain-related behaviour tests. AMPKα1 (catalytic alpha subunit of AMPK) expression was examined by immunohistochemistry and immunofluorescence analyses. The OA phenotype was also determined by μCT and MRI in non-human primates.
Metformin upregulated phosphorylated and total AMPK expression in articular cartilage tissue. Mild and more severe cartilage degeneration was observed at 6 and 12 weeks after DMM surgery, evidenced by markedly increased Osteoarthritis Research Society International scores, as well as reduced cartilage areas. The administration of metformin, commencing either before or after DMM surgery, caused significant reduction in cartilage degradation. Prominent synovial hyperplasia and osteophyte formation were observed at both 6 and 12 weeks after DMM surgery; these were significantly inhibited by treatment with metformin either before or after DMM surgery. The protective effects of metformin on OA development were not observed in AMPKα1 KO mice, suggesting that the chondroprotective effect of metformin is mediated by AMPK signalling. In addition, we demonstrated that treatment with metformin could also protect from OA progression in a partial medial meniscectomy animal model in non-human primates.
The present study suggests that metformin, administered shortly after joint injury, can limit OA development and progression in injury-induced OA animal models.
本研究旨在探讨二甲双胍对骨关节炎(OA)发展和进展的影响。
10 周龄野生型和 AMP 激活的蛋白激酶(AMPK)α1 敲除(KO)小鼠接受内侧半月板不稳定(DMM)手术。从 DMM 手术前 2 周或手术后 2 周开始给予二甲双胍(饮用水中 4mg/天)。DMM 手术后 6 周和 12 周处死小鼠。通过微计算机断层扫描(μCT)、组织学和疼痛相关行为测试分析 OA 表型。通过免疫组化和免疫荧光分析检测 AMPKα1(AMPK 的催化α亚基)的表达。非人类灵长类动物的 OA 表型也通过 μCT 和 MRI 进行评估。
二甲双胍上调关节软骨组织中磷酸化和总 AMPK 的表达。DMM 手术后 6 周和 12 周,观察到轻度和更严重的软骨退变,表现为 OA 研究协会国际评分明显升高,以及软骨面积减少。在 DMM 手术后开始给予二甲双胍治疗,无论是在手术前还是手术后,均可显著减轻软骨降解。在 DMM 手术后 6 周和 12 周均观察到明显的滑膜增生和骨赘形成;在 DMM 手术后开始给予二甲双胍治疗,均可显著抑制滑膜增生和骨赘形成。在 AMPKα1 KO 小鼠中,二甲双胍对 OA 发展没有保护作用,提示二甲双胍的软骨保护作用是通过 AMPK 信号转导介导的。此外,我们还证明,在非人类灵长类动物的部分内侧半月板切除术动物模型中,二甲双胍治疗也可以预防 OA 的进展。
本研究表明,在关节损伤后不久给予二甲双胍,可以限制损伤诱导的 OA 动物模型中 OA 的发展和进展。